Advancing Therapy in Type 2 Diabetes Mellitus with Early, Comprehensive Progression from Oral Agents to Insulin Therapy

Clinical Therapeutics

Volumn 29, Issue 6 PART 1, 2007, Pages 1236-1253

  Vinik, Aaron ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

basal insulin; early insulin therapy; early insulinization; type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TROGLITAZONE; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ARTICLE; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DIARRHEA; DIET RESTRICTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INSULIN TREATMENT; MEDICAL LITERATURE; MEDLINE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PUBLICATION; RISK REDUCTION; SIDE EFFECT; VOMITING; WEIGHT GAIN; BLOOD; DOSE RESPONSE; GLYCEMIC INDEX; METABOLISM; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 38449097526     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.005     Document Type: Article

References (114)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: United States. Available at:. General information (2005). www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf Accessed March 17, 2005
2. Centers For Disease Control and Prevention. Available at:. Diabetes: Disabling, deadly, and on the rise (2005). www.cdc.gov/nccdphp/aag/aag_ddt.htm Accessed March 17, 2005
3. Khaw K., Wareham N., Luben R., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322 (2001) 1-6
4. Coutinho M., Gerstein H., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
5. Haffner S., Stern M., Hazuda H., et al. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
6. Hu F., Stampfer M., Haffner S., et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25 (2002) 1129-1134
7. Turner R., and Holman R. Lessons from UK prospective diabetes study. Diabetes Res Clin Pratt 28 Suppl (1995) S151-S157
8. LeRoith D., Fonseca V., and Vinik A. Metabolic memory in diabetes-focus on insulin. Diabetes Metab Res Rev 21 (2005) 85-90
9. Artwohl M., Roden M., Waldhausl W., et al. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB J 18 (2004) 146-148
10. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26 (2003) 1589-1596
11. Virág L., and Szabó C. The therapeutic potential ofpoly (ADP-ribose) polymerase inhibitors. Pharmacol Rev 54 (2002) 375-429
12. Nishikawa T., Edelstein D., and Brownlee M. The missing link: A single unifying mechanism for diabetic complications. Kidney Int Suppl 58 Suppl 77 (2000) S-26-S-30
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
15. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287 (2002) 2563-2569
16. Buchanan T., Xiang A., Peters R., et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
17. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual b-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: A randomized, controlled trial. Ann Intern Med 128 (1998) 517-523
18. Wang Y., Ng M., Lee S., et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 26 (2003) 2410-2415
19. Nomiyama T., Tanaka Y., Piao L., et al. The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet 48 (2003) 138-141
20. Perseghin G., Petersen K., and Shulman G. Cellular mechanism of insulin resistance: Potential links with inflammation. Int J Obes 27 Suppl 3 (2003) S6-S11
21. Festa A., D'Agostino Jr. R., Howard G., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
22. Pradhan A., Manson J., and Rifai N. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
23. Shinozaki K., Kashiwagi A., Masada M., and Okamura T. Molecular mechanisms of impaired endothelial function associated with insulin resistance. Curr Drug Targets Cardiovasc Haematol Disord 4 (2004) 1-11
24. Hsueh W., and Quiñones M. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 92 Suppl (2003) 10J-17J
25. Meigs J., Hu F., Rifai N., and Manson J. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 291 (2004) 1978-1986
26. Brownlee M. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic complications. In: Rifkin H., and Porte D. (Eds). Diabetes Mellitus: Theory and Practice. 4 (1990), NY: Elsevier Science Publishing Co, Inc, New York 279-291
27. Bucala R., Tracey K., and Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87 (1991) 432-438
28. Vinik A., and Mehrabyan A. Diabetic neuropathies. Med Clin North Am 88 (2004) 947-999
29. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes selfimanagement-2002 update. Endocr Pract. 8 Suppl 1 (2002) 40-82
30. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
31. American Association of Clinical Endocrinologists. Available at:. Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement (February 2 2005). http://www.aace.com/pub/pdf/guidelines/OutpatientlmplementationPositionStatement.pdf Accessed March 14, 2005
32. Saydah S., Fradkin J., and Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
33. Resnick H., Foster G., Bardsley J., and Ratner R. Achievement of American Diabetes Association Clinical Practice Recommendations among U.S. adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey. Diabetes Care 29 (2006) 531-537
34. Shah B., Hux J., Laupacis A., et al. Clinical inertia in response to inadequate glycemic control: Do specialists differ from primary care physicians?. Diabetes Care 28 (2005) 600-606
35. Koro C., Bowlin S., Bourgeois N., and Fedder D. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care 27 (2004) 17-20
36. Turner R., Cull C., Frighi V., Holman R., and for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
37. Brown J., Nichols G., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
38. DeFronzo R., Goodman A., and for the Multicenter Metformin Study Group. Efficacy ofmetformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333 (1995) 541-549
39. Rosenstock J., Strow L., Rood J., et al. Rosiglitazone/metformin (RSG/MET) fixed dose combination (FDC) is effective and well-tolerated in drug-naive type 2 diabetes mellitus (T2DM) subjects with severe hyperglycemia. June 10-14, 2005. Abstracts of the 65th Scientific Sessions of the ADA (2005), San Diego, Calif Abstract 515-P
40. Rosenstock J., Sugimoto D., Strange P., et al. Triple therapy in type 2 diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29 (2006) 554-559
41. Vinik A. Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus. Insulin 1 (2006) 2-12
42. Wright A., Burden A., Paisey R., et al., for the U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
43. DeFronzo I. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131 (1999) 281-303
44. Bell D., and Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 8 (2002) 271-275
45. Cook M., Girman C., Stein P., et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28 (2005) 995-1000
46. Garber A., Larsen J., Schneider S., et al., for the Glyburide/Metformin Initial Therapy Study Group. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 4 (2002) 201-208
47. Garber A., Donovan D., Dandona P., et al. Efficacy of glyburide/metformin tablets compared with initial monatherapy in type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 3598-3604
48. Rosenstock J., Ferreira-Cornwell C., Weston W., et al. Rosiglitazone added early to glimepiride provides superior glycemic control than uptitration ofglimepiride alone in type 2 diabetes (T2DM). June 10-14. Posters of the 65th Scientific Sessions of the ADA (2005), San Diego, Calif Abstract 549-P
49. Dailey G., Noor M., Park J., et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patientswith type 2 diabetes: A randomized, double-blind trial. Am J Med 116 (2004) 223-229
50. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 29 (2006) 1963-1972
51. Peyrot M., Rubin R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
52. Hayward I., Manning W., Kaplan S., et al. Starting insulin therapy in patients with type 2 diabetes: Effectiveness, complications, and resource utilization. JAMA 278 (1997) 1663-1669
53. Hunt L., Valenzuela M., and Pugh J. NIDDM patients' fears and hopes about insulin therapy: The basis of patient reluctance. Diabetes Care 20 (1997) 292-298
54. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 15 (1999) 42-46
55. Gerstein H., Yale J., Harris S., et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 23 (2006) 736-742
56. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
57. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346 (2002) 393-403
58. Tuomilehto J., Lindström J., Eriksson J., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
59. Chiasson J., Josse R., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 290 (2003) 486-494
60. Chiasson J., Josse R., Gomis R., et al. Acarbose for prevention ofwpe 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
61. Torgerson J., Hauptman J., Boldrin M., and Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 (2004) 155-161
62. Cavaghan M., Ehrmann D., Byrne M., and Polonsky K. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100 (1997) 530-537
63. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54 (2005) 1150-1156
64. Xiang A., Peters R., Kjos S., et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55 (2006) 517-522
65. Xiang A., Peters R., Kjos S., et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: Impact on glucose tolerance and b-cell function. J Clin Endocrinol Metab 89 (2004) 2846-2851
66. Buchanan T., Xiang A., Peters R., et al. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 49 (2000) 782-788
67. Kahn S., Haffner S., Heise M., et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
68. Padwal R., Majumdar S., Johnson J., et al. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28 (2005) 736-744
69. The Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: Effects of life-style intervention and metformin. Diabetes 54 (2005) 2404-2414
70. Banerji M., Chaiken R., and Lebovitz H. Long-term normoglycemic remission in black newly diagnosed NIDDM subjects. Diabetes 45 (1996) 337-341
71. Ilkova H., Glaser B., Tunckale A., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 20 (1997) 1353-1356
72. Park S., and Choi S. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 19 (2003) 124-130
73. Ryan E., lines S., and Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 27 (2004) 1028-1032
74. Juhl C., Hollingdal M., Porksen N., et al. Influence of rosiglitazone treatment on β-cell function in type 2 diabetes: Evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 88 (2003) 3794-3800
75. McFarlane S., Chaiken R., Hirsch S., et al. Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 18 (2001) 10-16
76. Li Y., Xu W., Liao Z., et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell Function. Diabetes Care 27 (2004) 2597-2602
77. Scarlett J., Gray R., Griffin J., et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 5 (1982) 353-363
78. Strowig S., Avilés-Santa M., and Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27 (2004) 1577-1583
79. Strowig S., and Raskin P. Combination therapy using metFormin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 7 (2005) 633-641
80. Samanta A., Burden A., Jones G., and Clarkson L. The effect of short-term intensive insulin therapy in non-insulin-dependent diabetics who had Failed on sulphonylurea therapy. Diabetes Res 3 (1986) 269-271
81. Torella R., Salvatore T., Cozzolino D., et al. Restoration of sensitivity to sulFonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects. Diabetes Metab 17 (1991) 443-447
82. AIjada A., Ghanim H., Saadeh R., and Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 86 (2001) 450-453
83. AIjada A., Saadeh R., Assian E., et al. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 85 (2000) 2572-2575
84. Dandona P., Aljada A., Mohanty P., et al. Insulin inhibits intranuclear nuclear Factor κB and stimulates IκB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect. J Clin Endocrinol Metab 86 (2001) 3257-3265
85. Aljada A., and Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 49 (2000) 147-150
86. Steinberg H., Brechtel G., Johnson A., et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: A novel action of insulin to increase nitric oxide release. J Clin Invest 94 (1994) 1172-1179
87. Aljada A., Ghanim H., Mohanty P., et al. Insulin inhibits the pro-inflammatory transcription Factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue Factor (TF) and plasminogen activator inhibitor-1 (PAl-1 ) concentrations. J Clin Endocrinol Metab 87 (2002) 1419-1422
88. Galls Z., Sukhova G., Lark M., and Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94 (1994) 2493-2503
89. Ghanim H., Mohanty P., Aljada A., et al. Insulin reduces the pro-inflammatory transcription Factor, activation protein-1 (AP-1), in mononuclear cells (MNC) and plasma matrix metalloproteinase-9 (MMP-9) concentration. Diabetes. June 22-26. Abstracts of the 61st Scientific Sessions of the ADA (2001), Philadelphia, Pa. Abstract 1694-P
90. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
91. Malmberg K., and For the DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314 (1997) 1512-1515
92. Hansen T., Thiel S., Wouters P., et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 88 (2003) 1082-1088
93. Garg R., Kumbkarni Y., Aljada A., et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36 (2000) 430-435
94. Ghanim H., Garg R., Aljada A., et al. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86 (2001) 1306-1312
95. Mohanty P., Aljada A., and Ghanim H. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): Evidence of a potent anti-inflammatory effect. Diabetes. June 22-26. Abstracts of the 61st Scientific Sessions of the ADA (2001), Philadelphia, Pa. Abstract 276-OR
96. Mohanty P., Aljada A., Ghanim H., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
97. Vinik A., Stansberry K., and Barlow P. Rosiglitazone treatment increases nitric oxide production in human peripheral skin: A controlled clinical trial in patients with type 2 diabetes mellitus. J Diabetes Complications 17 (2003) 279-285
98. Vinik A., Ullal J., Parson H., et al. Pioglitazone treatment improves nitrosative stress in type 2 diabetes. Diabetes Care 29 (2006) 869-876
99. Rosenstock J., Schwartz S., Clark C., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
100. Riddle M., Rosenstock J., Gerich J., and for the Insulin Glargine Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of-type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
101. Shank M., Del Prato S., and Defronzo R. Bedtime insulin/daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM. Diabetes 44 (1995) 165-172
102. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
103. Raslova K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 66 (2004) 193-201
104. Vinik A., and Zhang Q. Adding insulin glargine versus rosiglitazone: Health-related quality of life impact in type 2 diabetes. Diabetes Care 30 (2007) 795-800
105. Saudek C., Duckworth W., Giobbie-Hurder A., et al. Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: A randomized clinical triaI. JAMA 276 (1996) 1322-1327
106. Freemantle N., Blonde L., Duhot D., et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28 (2005) 427-428
107. Barnett A., Dreyer M., Lange P., Serdarevic-Pehar M., and for the Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 29 (2006) 1282-1287
108. Stratton I., Adler A., Nell H., et al., for the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
109. Lam S., and See S. Exenatide: A novel incretin mimetic agent for treating type 2 diabetes mellitus. Cardiol Rev 14 (2006) 205-211
110. Heine R., Van Gaal L., Johns D., et al., for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled Wpe 2 diabetes: A randomized trial. Ann Intern Med 143 (2005) 559-569
111. Miller S., and St. Onge E. Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacotker 40 (2006) 1336-1343
112. Ahrén B., Pacini G., Foley J., and Schweizer A. Improved meal-related β-cell Function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28 (2005) 1936-1940
113. Januvia. prescribing information (2006), Merck & Co, Inc, Whitehouse Station, NJ
114. Vilsbøll T., Krarup T., Sonne J., et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88 (2003) 2706-2713